My ePortfolio Register   

AACR 2014 /
"Exciting" implications of bemacyclib study in the treatment of breast cancer

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1425
Rating:

Dr Amita Patnaik - South Texas Accelerated Research Therapeutics, San Antonio, USA

Dr Patnaik talks to ecancertv at the AACR conference about her work with cyclin-dependant kinase inhibitors in the treatment of breast cancer. Specifically, she looks at the development of bemaciclib and the dose and scheduling of the drug.

Read the article for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence